|
exo-miR-215-5p
|
Serum
|
Overexpression predicts poor disease-free survival in patients with HCC
|
[117]
|
|
miR-10b-5p
|
Serum
|
Potential biomarker for early-stage HCC
|
[117]
|
|
miR-18a, miR-221, miR-222, miR-224, miR-101, miR-106b, miR-122, miR195
|
Serum
|
Novel serological biomarkers for HCC
|
[43]
|
|
miR-122, miR-148a and AFP
|
Serum
|
Distinguish early HCC from liver cirrhosis
|
[41]
|
|
miR-122
|
Serum
|
Distinguish HCC from normal control
|
[41]
|
|
miR-9-3p
|
Serum
|
A therapeutic target for HCC
|
[69]
|
|
miR-665
|
Serum
|
A novel minimally invasive biomarker for HCC diagnosis and prognosis
|
[70]
|
|
miR-21
|
Serum
|
A potential biomarker for HCC diagnosis.
|
[40]
|
